The production value of biotechnology research and experimental development in Denmark has exhibited significant fluctuations from 2013 to 2023. Starting at 357.6 million euros in 2013, it saw notable year-on-year increases, especially in 2015 and 2017 with growth rates of 47.65% and 39.12%, respectively. Despite intermittent declines, such as a 17.42% drop in 2016 and a 12.91% decline in 2019, the overall trajectory has been upward. The value stood at 889.4 million euros in 2023, reflecting a sustained trend of growth.
In the last two years, the industry experienced moderate growth with a year-on-year increase of 4.79% in 2022 and 4.52% in 2023. The Compound Annual Growth Rate (CAGR) over the last five years (2018-2023) averaged at 2.08%, indicating steady long-term expansion despite occasional downturns.
The forecast for the upcoming years suggests a continued steady rise in production value, reaching an estimated 1080.0 million euros by 2028. The projected five-year CAGR from 2023 to 2028 is 3.02%, anticipating a 16.02% growth over this period.
Looking to the future, key trends to watch for include advancements in biotechnology applications, increased government and private sector investment, and the impact of emerging technologies such as genetic engineering and synthetic biology. These factors will likely drive further growth in Denmark's biotechnology R&D sector, with potential for transformative innovations and enhanced production capabilities.
